Holen Sie sich die Stockscreener-App
148.12
4.38%
6.22
Handel nachbörslich:
147.47
-0.65
-0.44%
Schlusskurs vom Vortag:
$141.90
Offen:
$142.47
24-Stunden-Volumen:
1.21M
Relative Volume:
0.82
Marktkapitalisierung:
$10.27B
Einnahmen:
$2.90B
Nettoeinkommen (Verlust:
$302.80M
KGV:
34.47
EPS:
4.2965
Netto-Cashflow:
$387.80M
1W Leistung:
+6.74%
1M Leistung:
+6.27%
6M Leistung:
-23.50%
1J Leistung:
-55.01%
1-Tages-Spanne:
$142.47
$148.35
1-Wochen-Bereich:
$139.46
$148.35
52-Wochen-Spanne:
$126.40
$354.88
Insulet Corp Stock (PODD) Company Profile
Firmenname
Insulet Corp
Sektor
Branche
Telefon
978-600-7000
Adresse
100 NAGOG PARK, ACTON, MA
Compare PODD vs ABT, MDT, SYK, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PODD
Insulet Corp
|
148.12 | 10.27B | 2.90B | 302.80M | 387.80M | 4.2965 |
ABT
Abbott Laboratories
|
102.51 | 177.38B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
96.59 | 123.55B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
307.08 | 117.79B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
46.01 | 66.68B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
90.09 | 51.93B | 6.30B | 1.07B | 1.09B | 1.8406 |
Insulet Corp Stock (PODD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-10-07 | Eingeleitet | Barclays | Equal Weight |
| 2026-08-06 | Herabstufung | BTIG Research | Buy → Neutral |
| 2026-08-06 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2026-08-06 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2026-08-06 | Herabstufung | Truist | Buy → Hold |
| 2026-08-06 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2026-08-05 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2026-07-28 | Fortgesetzt | UBS | Neutral |
| 2026-06-23 | Eingeleitet | Deutsche Bank | Buy |
| 2026-05-20 | Fortgesetzt | William Blair | Outperform |
| 2026-04-24 | Herabstufung | Rothschild & Co Redburn | Buy → Neutral |
| 2026-04-07 | Herabstufung | Citigroup | Buy → Neutral |
| 2026-01-27 | Fortgesetzt | TD Cowen | Hold |
| 2026-01-12 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-12-16 | Eingeleitet | Evercore ISI | Outperform |
| 2025-11-19 | Hochstufung | UBS | Neutral → Buy |
| 2025-10-21 | Fortgesetzt | Stifel | Buy |
| 2025-09-08 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-06-16 | Eingeleitet | Truist | Buy |
| 2025-05-30 | Eingeleitet | Goldman | Buy |
| 2025-05-13 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-04-29 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-03-06 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-11-06 | Eingeleitet | Bernstein | Outperform |
| 2024-05-30 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-05-07 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2023-12-21 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2023-12-04 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-02 | Hochstufung | Jefferies | Hold → Buy |
| 2023-08-21 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-08-21 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-01-26 | Eingeleitet | Wolfe Research | Peer Perform |
| 2022-11-04 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-18 | Eingeleitet | Barclays | Equal Weight |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-07-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-02-03 | Hochstufung | BTIG Research | Neutral → Buy |
| 2022-02-02 | Hochstufung | UBS | Neutral → Buy |
| 2022-01-31 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-07-21 | Fortgesetzt | Cowen | Outperform |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-01 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-03-19 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2021-01-29 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-07-28 | Eingeleitet | Wells Fargo | Overweight |
| 2020-04-24 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-04-03 | Eingeleitet | BofA/Merrill | Neutral |
| 2020-03-31 | Herabstufung | Berenberg | Buy → Hold |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2019-12-10 | Eingeleitet | CFRA | Sell |
| 2019-10-23 | Eingeleitet | Stifel | Hold |
| 2019-10-18 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2019-10-14 | Herabstufung | BTIG Research | Buy → Neutral |
| 2019-10-04 | Herabstufung | UBS | Buy → Neutral |
| 2019-10-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-08-06 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-06-10 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2019-05-06 | Hochstufung | BTIG Research | Neutral → Buy |
| 2018-04-20 | Eingeleitet | Berenberg | Buy |
| 2018-02-22 | Bestätigt | Barclays | Overweight |
| 2018-01-08 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2017-11-03 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2017-09-15 | Eingeleitet | Barclays | Overweight |
Alle ansehen
Insulet Corp Aktie (PODD) Neueste Nachrichten
Insulet Corp (GOV.DU) stock major holders - Yahoo Finance Australia
Global Digital Health and Remote Patient Monitoring Strategic Market Report, 2026-2031 | 20.2% CAGR to $80.8 Billion as Connected Care and Wearables Scale - GlobeNewswire Inc.
Bronstein, Gewirtz & Grossman (PODD) Investigation: Bronstein, Ge - The National Law Review
DexCom's G7 Shows Strong Results in Type 2 Diabetes CONNECT Study - Zacks Investment Research
Full Fed. Circ. Won't Revive Insulet's $59M Trade Secrets Win - Law360
MONDAY INVESTOR DEADLINE: Insulet Corporation (PODD) Investors wi - The National Law Review
PODD Investors Have Opportunity to Lead Insulet Corporation Class - The National Law Review
Insulet Corp. stock outperforms competitors on strong trading day - MarketWatch
Insulet Ordered to Defend Retirement Plan’s Target-Date Funds - Bloomberg Law News
Here's Why Insulet (PODD) is a Strong Growth Stock - Zacks Investment Research
Insulet Corp. stock underperforms Wednesday when compared to competitors - MarketWatch
Insulet Corp. stock outperforms competitors despite losses on the day - MarketWatch
Insulet Launches Omnipod Discover Diabetes Data Platform Nationwide - Medical Product Outsourcing
Insulet’s Omnipod Discover platform sees full market release in US - Fierce Biotech
A Look at Insulet Corp (PODD) After 3.4% Gain -- GF Value $398.3 - GuruFocus
Insulet Stock Gains as Traders Weigh Bullish Analyst Stance Against a Depressed Share Price - Quiver Quantitative
Insulet Corp. stock outperforms competitors on strong trading day - MarketWatch
PODD Maintains Buy Rating -- Price Target Lowered to $190 by Jef - GuruFocus
Insulet Launches Omnipod Discover Platform Across US - www.marketscreener.com
Insulet Launches Omnipod Discover Platform Across US - Yahoo Finance
Insulet launches Omnipod Discover data platform in U.S. By Investing.com - Investing.com South Africa
Insulet launches Omnipod Discover data platform in U.S. - Investing.com
Insulet launches Omnipod Discover data platform in the U.S. - StreetInsider
Insulet Announces Omnipod Discover Now Available in U.S. - Business Wire
Jefferies cuts Insulet stock price target on competition concerns - Investing.com
Insulet Corporation (PODD) PT Lowered to $190 at Jefferies - StreetInsider
Bronstein, Gewirtz & Grossman, LLC Encourages Bronstein, Gewirtz & Grossman (PODD) Investors to Inquire about Securities Investigation - ACCESS Newswire
Form 4 Insulet Corporation For: 11 October By Investing.com - Investing.com South Africa
Leerink Partners Adjusts Insulet Price Target to $143 From $145 - marketscreener.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Insulet Q2FY26 Results: Revenue up 23% YoY, adjusted EPS rises 41.5% - scanx.trade
Insulet Reports Q2 2026 Results: Full Earnings Call Transcript - Benzinga
Insulet Corp Lobbying Profile, 2018 - OpenSecrets
Insulet stock gets a Barclays Hold rating with USD 150 target - AD HOC NEWS
Insulet Corporation (PODD) Stock Forecasts - Yahoo Finance
Insulet Corp Share PricePODD, RNS News, Articles, Quotes, & Charts (NASDAQ:PODD) - Proactive financial news
Barclays Starts Insulet Corporation (PODD) at Equalweight - StreetInsider
Barclays Starts Insulet Corporation (PODD) at Equalweight - StreetInsider
Form 4 Insulet Corporation For: 6 October By Investing.com - Investing.com India
Ascensia Diabetes Care Expands Strategic Alliance with Insulet Corporation by Signing Commercial Agreement - Lelezard
Form 4 Insulet Corporation For: 6 October By Investing.com - Investing.com South Africa
Insulet (PODD) CFO Flavia Pease has 1,882 shares withheld for vesting taxes at $130.79 each. - Stock Titan
Insulet Corp. stock outperforms competitors on strong trading day - MarketWatch
PODD Should I Buy - Intellectia AI
Form 4 Insulet Corporation For: 2 October By Investing.com - Investing.com South Africa
A director receives 141 stock units instead of cash compensation at Insulet (PODD). - Stock Titan
Stock units replace cash pay for Insulet (PODD) director Huffines, who received 178 units. - Stock Titan
Important Notice to Long-Term Shareholders of Beta Bionics, - GlobeNewswire
Press Release: Insulet to Announce Third Quarter 2026 Financial Results on November 4, 2026 - Moomoo
Insulet to Announce Third Quarter 2026 Financial Results on November 4, 2026 - Business Wire
Finanzdaten der Insulet Corp-Aktie (PODD)
Umsatz
Nettogewinn
Free Cashflow
ENV
Insulet Corp-Aktie (PODD) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| WEATHERMAN ELIZABETH H | Director |
Jun 03 '26 |
Buy |
144.20 |
3,450 |
497,490 |
10,352 |
| BORIO LUCIANA | Director |
Jun 03 '26 |
Proposed Sale |
143.26 |
418 |
59,885 |
0 |
| STONESIFER TIMOTHY C. | Director |
Jun 03 '26 |
Buy |
143.51 |
2,790 |
400,393 |
9,041 |
| BORIO LUCIANA | Director |
Jun 03 '26 |
Sale |
143.27 |
418 |
59,887 |
4,329 |
| MINOGUE MICHAEL R | Director |
Feb 25 '26 |
Buy |
246.23 |
2,030 |
499,847 |
17,483 |
| McEvoy Ashley | President and CEO |
Feb 20 '26 |
Buy |
239.35 |
4,300 |
1,029,205 |
13,916 |
| Frederick Wayne A.I. | Director |
Dec 15 '25 |
Proposed Sale |
293.09 |
1,851 |
542,500 |
0 |
| Frederick Wayne A.I. | Director |
Dec 15 '25 |
Sale |
293.09 |
1,851 |
542,510 |
2,158 |
| STONESIFER TIMOTHY C. | Director |
Dec 05 '25 |
Buy |
311.73 |
962 |
299,884 |
4,591 |
| Manea Dan | Former Officer |
Nov 26 '25 |
Proposed Sale |
326.64 |
4,475 |
1,461,716 |
0 |
0.09%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):